PE20190511A1 - Piridinas sustituidas con heteroarilo y metodos de uso - Google Patents
Piridinas sustituidas con heteroarilo y metodos de usoInfo
- Publication number
- PE20190511A1 PE20190511A1 PE2018003091A PE2018003091A PE20190511A1 PE 20190511 A1 PE20190511 A1 PE 20190511A1 PE 2018003091 A PE2018003091 A PE 2018003091A PE 2018003091 A PE2018003091 A PE 2018003091A PE 20190511 A1 PE20190511 A1 PE 20190511A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- refers
- substituted
- chronic obstructive
- cystic fibrosis
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a compuestos de piridina sustituidos de Formula I, donde X1 y X2 son H, halo, -OH, entre otros; R1 es alcoxi C1-4, alquilo C1-4 opcionalmente sustituido con uno o mas -OH, entre otros; R2 es un heteroarilo monociclico de 5-6 miembros que comprende 1, 2 o 3 heteroatomos seleccionados entre O, S y N, el cual esta sustituido con uno o mas grupos R3; R3 es alquilo C1-4, cicloalquilo C3-7, halo, -CN, -OH, entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son utiles para tratamiento de enfermedades y afecciones mediadas y moduladas por el regulador de conductancia transmembrana de la fibrosis quistica (CFTR) tales como fibrosis quistica, insuficiencia pancreatica, sindrome de Sjogren, enfermedad pulmonar obstructiva cronica (EPOC) o enfermedad de las vias respiratorias obstructiva cronica (EVROC)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345315P | 2016-06-03 | 2016-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190511A1 true PE20190511A1 (es) | 2019-04-10 |
Family
ID=59014678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003091A PE20190511A1 (es) | 2016-06-03 | 2017-05-24 | Piridinas sustituidas con heteroarilo y metodos de uso |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10138227B2 (es) |
| EP (1) | EP3464282B1 (es) |
| JP (3) | JP6968094B2 (es) |
| KR (2) | KR102469995B1 (es) |
| CN (2) | CN114671864B (es) |
| AR (2) | AR108672A1 (es) |
| AU (3) | AU2017273215B2 (es) |
| CA (1) | CA3022216A1 (es) |
| CL (1) | CL2018003323A1 (es) |
| CO (1) | CO2018012171A2 (es) |
| CR (1) | CR20180547A (es) |
| CY (1) | CY1124031T1 (es) |
| DK (1) | DK3464282T3 (es) |
| DO (1) | DOP2018000257A (es) |
| EC (1) | ECSP18094790A (es) |
| ES (1) | ES2806873T3 (es) |
| HR (1) | HRP20201068T1 (es) |
| HU (1) | HUE050248T2 (es) |
| IL (3) | IL288243B2 (es) |
| LT (1) | LT3464282T (es) |
| MX (2) | MX385054B (es) |
| MY (1) | MY199604A (es) |
| NZ (2) | NZ788542A (es) |
| PE (1) | PE20190511A1 (es) |
| PH (1) | PH12018502534B1 (es) |
| PL (1) | PL3464282T3 (es) |
| PT (1) | PT3464282T (es) |
| RS (1) | RS60574B1 (es) |
| RU (2) | RU2756743C2 (es) |
| SG (1) | SG11201808842VA (es) |
| SI (1) | SI3464282T1 (es) |
| SM (1) | SMT202000394T1 (es) |
| TW (4) | TWI797926B (es) |
| UY (2) | UY37272A (es) |
| WO (1) | WO2017208115A1 (es) |
| ZA (1) | ZA201808423B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100921397B1 (ko) * | 2009-02-09 | 2009-10-14 | (주)오엠티 | 인쇄회로기판의 세척장비 및 이를 이용한 세척방법 |
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| BR112019006213A2 (pt) | 2016-09-30 | 2019-06-18 | Vertex Pharma | modulador de regulador de condutância transmembranar de fibrose cística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador |
| LT3551622T (lt) | 2016-12-09 | 2021-02-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorius, farmacinė kompozicija, gydymo būdai, ir moduliatoriaus gamybos būdas |
| WO2018116185A1 (en) | 2016-12-20 | 2018-06-28 | AbbVie S.à.r.l. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
| CA3071278A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| TWI719349B (zh) | 2017-10-19 | 2021-02-21 | 美商維泰克斯製藥公司 | Ｃｆｔｒ調節劑之結晶形式及組合物 |
| WO2019113476A2 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019161078A1 (en) | 2018-02-15 | 2019-08-22 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| IT201900000687A1 (it) | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento della fibrosi cistica |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
| IL302295A (en) | 2019-08-14 | 2023-06-01 | Vertex Pharma | CFTR modulator preparation process |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| PE20221461A1 (es) * | 2019-11-12 | 2022-09-21 | Genzyme Corp | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr |
| BR112023002651A2 (pt) | 2020-08-20 | 2023-04-04 | Univ Leland Stanford Junior | Métodos de tratamento de doenças respiratórias definidas por hipersecreção de muco |
| EP4259139A1 (en) | 2020-12-10 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| EP4274828A1 (en) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| JP2024532152A (ja) | 2021-08-19 | 2024-09-05 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | ジアミド抵抗性有害生物の防除方法及びそのための化合物 |
| TW202421102A (zh) | 2022-09-15 | 2024-06-01 | 瑞士商愛杜西亞製藥有限公司 | 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合 |
| CA3267795A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | MACROCYCLICAL CFTR MODULATORS |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094374A2 (en) * | 2004-03-30 | 2005-10-13 | The Regents Of The University Of California | Hydrazide-containing cftr inhibitor compounds and uses thereof |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PL2489659T3 (pl) | 2004-06-24 | 2018-06-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą atp |
| US8283351B2 (en) * | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
| CA2688004C (en) | 2007-05-25 | 2016-07-05 | Vertex Pharmaceuticals Incorporated | Thienopyridone compounds for use as modulators of cystic fibrosis transmembrane conductance regulator |
| NZ585789A (en) | 2007-12-10 | 2012-03-30 | Novartis Ag | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel |
| CA2709301C (en) | 2007-12-13 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20110074916A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｎ-(4-(7-아자비시클로［2.2.1］헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태 |
| EA018891B1 (ru) * | 2008-10-23 | 2013-11-29 | Вертекс Фармасьютикалз, Инкорпорейтед | Модуляторы регулятора трансмембранной проводимости при муковисцидозе |
| WO2010078103A1 (en) | 2008-12-30 | 2010-07-08 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US8247436B2 (en) * | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| HUE025653T2 (hu) | 2010-10-08 | 2016-04-28 | Nivalis Therapeutics Inc | Új, szubsztituált kinolin-vegyületek S-nitrozoglutation-reduktáz inhibitorokként |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| ES2558457T3 (es) * | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| EP2755652B1 (en) * | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
| HUE041740T2 (hu) | 2011-09-20 | 2019-05-28 | Univ North Carolina Chapel Hill | Nátriumcsatornák szabályozása PLUNC-fehérjékkel |
| MX368263B (es) | 2013-05-07 | 2019-09-26 | Galapagos Nv | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. |
| HUE040366T2 (hu) | 2013-08-08 | 2019-03-28 | Galapagos Nv | CFTR modulátor tieno[2,3-c]piránok |
| CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| PT3212189T (pt) | 2014-10-31 | 2020-11-12 | Galapagos Nv | Cromanos substituídos e método de utilização |
| MX2017005663A (es) | 2014-10-31 | 2018-03-01 | Abbvie Sarl | Tetrahidropiranos sustituidos y metodo de uso. |
| HK1249893A1 (zh) * | 2015-03-31 | 2018-11-16 | Vertex Pharmaceuticals (Europe) Limited | 氘代vx-661 |
| CR20170595A (es) * | 2015-06-02 | 2018-04-27 | Galapagos Nv | Piridinas sustituidas y método de uso |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| KR20180083323A (ko) | 2015-10-09 | 2018-07-20 | 애브비 에스.에이.알.엘. | N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법 |
| CA3001094A1 (en) | 2015-10-09 | 2017-04-13 | Abbvie S.A.R.L. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| WO2017187321A1 (en) | 2016-04-26 | 2017-11-02 | AbbVie S.à.r.l. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
-
2017
- 2017-05-23 US US15/602,892 patent/US10138227B2/en active Active
- 2017-05-24 DK DK17728272.0T patent/DK3464282T3/da active
- 2017-05-24 LT LTEP17728272.0T patent/LT3464282T/lt unknown
- 2017-05-24 RU RU2018138707A patent/RU2756743C2/ru active
- 2017-05-24 PL PL17728272T patent/PL3464282T3/pl unknown
- 2017-05-24 RS RS20200829A patent/RS60574B1/sr unknown
- 2017-05-24 SI SI201730320T patent/SI3464282T1/sl unknown
- 2017-05-24 SG SG11201808842VA patent/SG11201808842VA/en unknown
- 2017-05-24 AU AU2017273215A patent/AU2017273215B2/en active Active
- 2017-05-24 IL IL288243A patent/IL288243B2/en unknown
- 2017-05-24 IL IL303196A patent/IL303196B2/en unknown
- 2017-05-24 CN CN202210433324.9A patent/CN114671864B/zh active Active
- 2017-05-24 PE PE2018003091A patent/PE20190511A1/es unknown
- 2017-05-24 MX MX2018014758A patent/MX385054B/es unknown
- 2017-05-24 RU RU2021127810A patent/RU2021127810A/ru unknown
- 2017-05-24 KR KR1020187031861A patent/KR102469995B1/ko active Active
- 2017-05-24 HU HUE17728272A patent/HUE050248T2/hu unknown
- 2017-05-24 CA CA3022216A patent/CA3022216A1/en active Pending
- 2017-05-24 WO PCT/IB2017/053068 patent/WO2017208115A1/en not_active Ceased
- 2017-05-24 JP JP2018552704A patent/JP6968094B2/ja active Active
- 2017-05-24 HR HRP20201068TT patent/HRP20201068T1/hr unknown
- 2017-05-24 KR KR1020227040379A patent/KR102719916B1/ko active Active
- 2017-05-24 CN CN201780033214.0A patent/CN109311864B/zh active Active
- 2017-05-24 ES ES17728272T patent/ES2806873T3/es active Active
- 2017-05-24 NZ NZ788542A patent/NZ788542A/en unknown
- 2017-05-24 SM SM20200394T patent/SMT202000394T1/it unknown
- 2017-05-24 CR CR20180547A patent/CR20180547A/es unknown
- 2017-05-24 NZ NZ747222A patent/NZ747222A/en unknown
- 2017-05-24 MY MYPI2018703798A patent/MY199604A/en unknown
- 2017-05-24 EP EP17728272.0A patent/EP3464282B1/en active Active
- 2017-05-24 PT PT177282720T patent/PT3464282T/pt unknown
- 2017-06-02 UY UY0001037272A patent/UY37272A/es active IP Right Grant
- 2017-06-02 AR ARP170101516A patent/AR108672A1/es active IP Right Grant
- 2017-06-02 UY UY0001040612A patent/UY40612A/es not_active Application Discontinuation
- 2017-06-03 TW TW110149319A patent/TWI797926B/zh active
- 2017-06-03 TW TW112108367A patent/TWI849782B/zh active
- 2017-06-03 TW TW113122971A patent/TW202515560A/zh unknown
- 2017-06-03 TW TW106118418A patent/TWI752961B/zh active
-
2018
- 2018-10-16 IL IL262415A patent/IL262415B/en unknown
- 2018-10-19 US US16/165,662 patent/US10604515B2/en active Active
- 2018-11-13 CO CONC2018/0012171A patent/CO2018012171A2/es unknown
- 2018-11-22 CL CL2018003323A patent/CL2018003323A1/es unknown
- 2018-11-26 DO DO2018000257A patent/DOP2018000257A/es unknown
- 2018-11-29 PH PH12018502534A patent/PH12018502534B1/en unknown
- 2018-11-29 MX MX2021009322A patent/MX2021009322A/es unknown
- 2018-12-13 ZA ZA2018/08423A patent/ZA201808423B/en unknown
- 2018-12-26 EC ECSENADI201894790A patent/ECSP18094790A/es unknown
-
2020
- 2020-07-14 CY CY20201100646T patent/CY1124031T1/el unknown
-
2021
- 2021-10-25 JP JP2021173679A patent/JP7392211B2/ja active Active
- 2021-12-07 AU AU2021282409A patent/AU2021282409B2/en not_active Expired - Fee Related
-
2022
- 2022-02-18 AR ARP220100344A patent/AR124916A2/es unknown
-
2023
- 2023-03-27 JP JP2023049450A patent/JP7622122B2/ja active Active
-
2024
- 2024-04-16 AU AU2024202468A patent/AU2024202468A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190511A1 (es) | Piridinas sustituidas con heteroarilo y metodos de uso | |
| DOP2018000020A (es) | Tricíclicos sustituidos y método para usarlos | |
| AR133180A2 (es) | Cromanos sustituidos y métodos para su uso | |
| CL2018000911A1 (es) | Pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas y método de uso | |
| PE20170502A1 (es) | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 | |
| CL2019002103A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa. | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| PE20181197A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| CL2017000824A1 (es) | Moduladores de regulador de conducta de transmembranas de fibrosis cística | |
| CL2016002888A1 (es) | Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras. | |
| PE20151144A1 (es) | Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias | |
| CY1122500T1 (el) | Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων | |
| JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
| PE20141944A1 (es) | N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina | |
| PE20150974A1 (es) | Derivados de piridina | |
| EA201891143A1 (ru) | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 | |
| ECSP13012893A (es) | Ureas asimétricas y usos médicos de las mismas | |
| EA202092620A1 (ru) | Соли и твердые формы монобактамного антибиотика | |
| CL2012002570A1 (es) | Compuestos derivados de ácido 2-(3heteroaril-amino-1,2,3,4-tetrahidro-9h-carbazol)-acético, composicion farnaceutica que los comprende, y su uso como medicamentos, en la profilaxis y/o el tratamiento de patologias mediadas por la modulacion de receptores de prostaglandinas d2, como trastornos alergicos o inmunitarios. | |
| CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| PE20150184A1 (es) | Derivados de ariletinilo | |
| PE20181071A1 (es) | Derivados novedosos de diamino piridina | |
| CO6741219A2 (es) | Inhibidores de catepsina c | |
| AR075032A1 (es) | Pirazinonas sustituidas |